patient 18 years old and more
with multiple sclerosis according to the criteria of Mac Donald 2010 : relapsing-remitting (RR), secondary-progressive (SP) or primary-progressive (PP)
for which treatment with dimethyl-fumarate has been prescribed
followed at the Rothschild Foundation in the Neurology Department
having given written consent to participation in the study
